Showing 1 - 10 of 19
Banks continue to differ in many ways, for instance with respect to business models, growth strategies, or financial health. Neglecting these differences confuses inefficiency with heterogeneity while sub-sample estimation prohibits efficiency comparisons across different samples. We use a...
Persistent link: https://www.econbiz.de/10010295952
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...
Persistent link: https://www.econbiz.de/10010300533
Dieser Beitrag diskutiert den Einfluss vergangener gesundheitspolitischer Reformgesetze in Deutschland auf Wahl- und …
Persistent link: https://www.econbiz.de/10010300558
The quiet life hypothesis (QLH) posits that banks enjoy the advantages of market power in terms of foregone revenues or cost savings. We suggest a united approach to measure competition and efficiency simultaneously to test this hypothesis. We estimate bank-specific Lerner indices as measures of...
Persistent link: https://www.econbiz.de/10010271346
The "quiet life hypothesis (QLH)" posits that banks enjoy the advantages of market power in terms of foregone revenues or cost savings. We suggest a united approach to measure competition and efficiency simultaneously to test this hypothesis. We estimate bank-specific Lerner indices as measures...
Persistent link: https://www.econbiz.de/10003783101
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...
Persistent link: https://www.econbiz.de/10009492625
This paper discusses the influence of recent health care reform acts in Germany on choice, guidance and access from the perspective of patients, insured, insurers, and health care providers. Particular emphasis is put on health policy reforms since 2004, i.e. the Social Health Insurance...
Persistent link: https://www.econbiz.de/10009500545
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10009522774
Persistent link: https://www.econbiz.de/10009713495
Persistent link: https://www.econbiz.de/10011541102